Participated · Series C · Feb 2026

Neurent Medical is a med-tech company focused on transforming care for chronic inflammatory sinonasal diseases, beginning with chronic rhinitis. Its flagship NEUROMARK System employs proprietary Impedance Controlled Radiofrequency technology to gently disrupt hyperactive posterior nasal nerves, providing durable symptom relief with minimal downtime. The company positions the platform as a differentiated, clinician-friendly alternative that tackles the root cause of rhinitis rather than merely managing symptoms. Headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts, Neurent Medical is expanding commercial availability and building further clinical evidence to support adoption. The newly secured capital will accelerate market penetration, support additional clinical studies across broader populations, and fund development of future indication and product pipeline extensions. The firm has attracted prominent medtech investors and added new board members to guide this next growth phase. No revenue or user metrics were disclosed in the article, but leadership emphasizes scaling sales and broadening evidence as immediate priorities.

Participated · Series B · Jan 2026

Founded in 2016 by Drs. Anton Bespalov, Hans Moebius and Rao Vepachedu, Exciva focuses on therapies for neuropsychiatric symptoms in Alzheimer’s disease dementia and related brain disorders. Its lead candidate, Deraphan, combines two CNS-active compounds designed to reduce agitation in Alzheimer’s patients. The company is currently preparing and financing a Phase 2 clinical study to evaluate Deraphan’s therapeutic potential. Exciva leverages proprietary discovery capabilities to identify synergistic compound combinations addressing unmet neuropsychiatric needs. The latest capital infusion strengthens its balance sheet and extends runway through critical mid-stage clinical development. While the company has not disclosed revenue or patient enrollment numbers, the new financing underscores investor confidence in its scientific approach and market opportunity. The refreshed board now includes representatives from key new and existing investors, ensuring broad strategic guidance as the program advances.

Led · Series B · Mar 2025

Neuromod Devices Ltd., founded in 2010 and headquartered in Dublin, Ireland, develops and commercialises Lenire, a non‑invasive bimodal neuromodulation device for tinnitus. Lenire delivers mild electrical pulses to the tongue via a Tonguetip® combined with auditory stimulation to drive changes in the brain and relieve tinnitus symptoms. The device achieved FDA De Novo approval in March 2023 and holds CE marking in Europe, and its pivotal controlled trial was published in Nature Communications. Neuromod has commercial traction with Lenire available in more than 100 clinics across the USA and in clinics in 14 European countries; 35 USVA facilities have been trained to provide the treatment. Real‑world evidence includes a base of over 1,500 patients and clinic-level results showing high rates of clinically significant improvement. The company plans to use new funding to accelerate sustainable commercial expansion in the USA and Europe and to grow opportunities within the US Department of Veteran Affairs. Neuromod Devices, founded in 2010 by Dr. Ross O’Neill, is a Dublin, Ireland–based medical technology company that designs neuromodulation technologies for underserved chronic conditions. Its lead product, Lenire, is a bimodal neuromodulation device that delivers mild electrical pulses to the tongue via the Tonguetip® combined with auditory stimulation through headphones to treat tinnitus. Lenire has been used in large-scale clinical trials with over 700 patients, is available throughout Europe, and recently received FDA De Novo approval. Since its prior funding round in October 2020 the company has commercialised Lenire across Europe and established a wholly owned US subsidiary, Neuromod USA Inc. The company intends to use the new funding to launch Lenire in the US, pursue opportunities with the US Departments of Defense and Veteran Affairs, expand availability in additional European countries, and advance next-generation product development. The financing structure (equity plus venture debt) supports its planned US market entry and continued commercial expansion. Neuromod is an Irish medical technology company that designs and develops neuromodulation technologies to address tinnitus. Its core product, Lenire®, is a CE-marked, non-invasive bimodal neuromodulation device commercially available in Ireland, Belgium and Germany. The company published results from a 12-week, 326-patient clinical trial in Science Translational Medicine showing that more than 80% of compliant participants saw sustained improvements at 12 months. Proceeds from the €10.5 million Series B will be used to expand European commercialisation, scale up manufacturing, progress a U.S. FDA strategy, and pursue opportunities with the U.S. Department of Veteran Affairs. Neuromod plans to recruit roughly 40 employees over the next 12 months with roles based in Ireland and Germany. The company was founded in 2010 and is headquartered in the Digital Hub, Dublin. Neuromod Devices develops non-invasive neuromodulation technologies and markets Lenire®, a CE‑marked bimodal neuromodulation tinnitus treatment for use under healthcare supervision in Europe. The company opened a Centre of Excellence in tinnitus care in Dublin and plans additional European treatment centres, including one in Hannover by end of 2019 and more during 2020. Neuromod says it has conducted the largest and longest follow-up clinical trials for tinnitus to confirm Lenire®’s efficacy. Proceeds from the recent financing will be used to accelerate European commercialisation and scale manufacturing to meet anticipated demand. The company is also progressing a U.S. regulatory strategy aimed at an FDA submission to enable U.S. market entry. Neuromod is headquartered in the Digital Hub, Dublin, and was founded in 2010 as a spin‑out from Maynooth University. Neuromod Devices develops mutebutton®, a non-invasive bi-modal neuromodulation device that delivers simultaneous auditory stimulation in the ear and sensory stimulation on the tongue to promote beneficial neuroplasticity for chronic tinnitus. The company holds a CE mark for the mutebutton® (awarded October 2014) and a US patent for its technology (awarded September 2015). Neuromod plans to use recent financing to advance dose optimisation and patient sub-typing research and to commence US clinical trials. The company targets an international launch of mutebutton® in 2018. Manufacturing partners M&M Qualtech and Molex and support from Enterprise Ireland are cited as contributors to the company’s growth. To date Neuromod has raised over €8 million ($9 million).

Participated · Series B · Jan 2025

XyloCor Therapeutics is a private, clinical-stage biopharmaceutical company based in King of Prussia, Pa., developing one-time gene therapies to transform outcomes for patients with cardiovascular disease. Its lead product, XC001 (encoberminogene rezmadenovec), is designed to promote new blood vessel growth in the heart to restore blood flow and reduce ischemic chest pain while minimizing systemic toxicity through local administration. Positive Phase 1/2 (EXACT-1) data published in Circulation: Cardiovascular Interventions demonstrated potential disease-modifying effects in refractory angina. XyloCor plans two randomized, double-blind Phase 2 trials in 2025: a Phase 2b EXACT-2 study using catheter-based endocardial delivery in refractory angina and a second trial evaluating XC001 as an adjunct to coronary artery bypass graft surgery (CABG). The company also has a preclinical candidate, XC002, in discovery for treating cardiac tissue damage after heart attacks. The $67.5 million Series B will fund completion of the two Phase 2 trials and support continued clinical development. XyloCor Therapeutics is developing XC001, an investigational gene therapy intended to promote angiogenesis in the heart for patients with refractory angina; XC001 is being studied in the Phase 1/2 EXACT trial. XC001 has Fast Track designation from the FDA and an open IND, and the EXACT trial—an open-label, dose-escalation study initiated in 2020—is ongoing at U.S. cardiovascular research sites. The company is also developing a second preclinical candidate, XC002, for cardiac tissue damage after heart attacks. XyloCor plans to expand XC001’s clinical program, including initiating a new trial evaluating XC001 as an adjunctive therapy to augment the effectiveness of coronary artery bypass graft surgery (CABG). Financially, the company closed an additional $22.6 million financing that builds on its 2018 Series A, bringing total investment to $41.9 million to date. XyloCor is headquartered in Malvern, Pa., was co-founded by Ronald Crystal, MD, and Todd Rosengart, MD, and holds an exclusive license from Cornell University. XyloCor Therapeutics is a private clinical-stage biopharmaceutical company developing gene therapies to address unmet needs in cardiovascular disease. Its lead product, XC001, is an angiogenic gene therapy intended as a one-time treatment to improve exercise tolerance in patients with refractory angina, and the company also has a discovery-stage program, XC002, aimed at cardiac tissue regeneration after heart attacks. The U.S. FDA granted Fast Track designation to XC001, an IND is open, and XyloCor intends to commence clinical trials in 2019. Proceeds from the recently closed $17 million Series A will be used to advance XC001's development and to expand the company’s business and operational structure. The company is led by CEO Al Gianchetti and has expanded its board to include industry investors and academic founders, with a worldwide license to develop and commercialize XC001 from Weill Cornell Medicine. XyloCor positions XC001 as a potential option for patients with refractory angina who have no remaining standard treatment choices.

Participated · Equity · Feb 2024

Mainstay Medical Holdings is a Dublin, Ireland–based medical device company focused on commercializing its implantable Restorative Neurostimulation system, ReActiv8, for people with disabling mechanical chronic low back pain (CLBP). Led by CEO Jason Hannon, the company is advancing rapid commercial growth and insurance coverage for ReActiv8. It announced a US$125M equity financing to support that growth and its operations. Mainstay plans to use the proceeds to expand ReActiv8 commercial activity in the U.S., Europe and Australia, to fund additional post‑market clinical studies and research, and for general operations. The company operates subsidiaries in Ireland, the United States, Australia, Germany and the Netherlands. The financing is positioned to accelerate Mainstay’s commercial and clinical initiatives for ReActiv8. Mainstay Medical develops and commercializes ReActiv8, an active implantable neurostimulation device intended to treat adults with intractable chronic low back pain by electrically stimulating the L2 medial branch to elicit multifidus muscle contraction. ReActiv8 holds a CE Mark for the EEA, is admitted to the Australian Register of Therapeutic Goods and included on Australia’s Prostheses List, and is FDA approved in the U.S. The company says ReActiv8 has been building clinical validation in Germany ahead of wider commercial availability. Mainstay is headquartered in Dublin, Ireland, with subsidiaries in the United States, Australia, Germany and the Netherlands. The company plans a U.S. commercial launch in early 2021 and intends to expand commercialization in Europe and Australia, conduct additional post-market clinical studies and continue research. Mainstay recently completed a material equity financing to support those commercial and clinical initiatives and general operations.